Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease)
Abstract Thromboangiitis obliterans (TAO), also known as Buerger’s Disease, is an occlusive vasculitis linked with high morbidity and amputation risk. To date, TAO is deemed incurable due to the lack of a definitive treatment. The immune system and inflammation are proposed to play a central role in...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13287-018-0901-6 |
id |
doaj-19074c2d17e24a6d8d732d8b621eecb0 |
---|---|
record_format |
Article |
spelling |
doaj-19074c2d17e24a6d8d732d8b621eecb02020-11-25T01:11:58ZengBMCStem Cell Research & Therapy1757-65122018-05-01911610.1186/s13287-018-0901-6Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease)Jorge D. Martin-Rufino0Francisco S. Lozano1Alba M. Redondo2Eva M. Villaron3Raquel Rueda4Rafael Fernandez-Samos5Fermin Sanchez-Guijo6Department of Hematology, Cell Therapy Unit, IBSAL-Hospital Universitario de SalamancaDepartment of Angiology and Vascular Surgery, IBSAL-Hospital Universitario de SalamancaDepartment of Hematology, Cell Therapy Unit, IBSAL-Hospital Universitario de SalamancaDepartment of Hematology, Cell Therapy Unit, IBSAL-Hospital Universitario de SalamancaDepartment of Radiology, Hospital de LeonDepartment of Angiology and Vascular Surgery, Hospital de LeonDepartment of Hematology, Cell Therapy Unit, IBSAL-Hospital Universitario de SalamancaAbstract Thromboangiitis obliterans (TAO), also known as Buerger’s Disease, is an occlusive vasculitis linked with high morbidity and amputation risk. To date, TAO is deemed incurable due to the lack of a definitive treatment. The immune system and inflammation are proposed to play a central role in TAO pathogenesis. Due to their immunomodulatory effects, mesenchymal stromal cells (MSCs) are the subject of intense research for the treatment of a wide range of immune-mediated diseases. Thus far, local intramuscular injections of autologous or allogeneic MSCs have shown promising results in TAO. However, sequential intravenous allogeneic MSC administration has not yet been explored, which we hypothesized could exert a systemic anti-inflammatory effect in the vasculature and modulate the immune response. Here, we report the first case of a TAO patient at amputation risk treated with four sequential intravenous infusions of bone marrow-derived allogeneic MSCs from a healthy donor. Following administration, there was significant regression of foot skin ulcers and improvements in rest pain, Walking Impairment Questionnaire scores, and quality of life. Sixteen months after the infusion, the patient had not required any further amputations. This report highlights the potential of sequential allogeneic MSC infusions as an effective treatment for TAO, warranting further studies to compare this approach with the more conventionally used intramuscular MSC administration and other cell-based therapies.http://link.springer.com/article/10.1186/s13287-018-0901-6Allogeneic mesenchymal stromal cellsThromboangiitis obliteransCell transplantation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jorge D. Martin-Rufino Francisco S. Lozano Alba M. Redondo Eva M. Villaron Raquel Rueda Rafael Fernandez-Samos Fermin Sanchez-Guijo |
spellingShingle |
Jorge D. Martin-Rufino Francisco S. Lozano Alba M. Redondo Eva M. Villaron Raquel Rueda Rafael Fernandez-Samos Fermin Sanchez-Guijo Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) Stem Cell Research & Therapy Allogeneic mesenchymal stromal cells Thromboangiitis obliterans Cell transplantation |
author_facet |
Jorge D. Martin-Rufino Francisco S. Lozano Alba M. Redondo Eva M. Villaron Raquel Rueda Rafael Fernandez-Samos Fermin Sanchez-Guijo |
author_sort |
Jorge D. Martin-Rufino |
title |
Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) |
title_short |
Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) |
title_full |
Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) |
title_fullStr |
Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) |
title_full_unstemmed |
Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease) |
title_sort |
sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (buerger’s disease) |
publisher |
BMC |
series |
Stem Cell Research & Therapy |
issn |
1757-6512 |
publishDate |
2018-05-01 |
description |
Abstract Thromboangiitis obliterans (TAO), also known as Buerger’s Disease, is an occlusive vasculitis linked with high morbidity and amputation risk. To date, TAO is deemed incurable due to the lack of a definitive treatment. The immune system and inflammation are proposed to play a central role in TAO pathogenesis. Due to their immunomodulatory effects, mesenchymal stromal cells (MSCs) are the subject of intense research for the treatment of a wide range of immune-mediated diseases. Thus far, local intramuscular injections of autologous or allogeneic MSCs have shown promising results in TAO. However, sequential intravenous allogeneic MSC administration has not yet been explored, which we hypothesized could exert a systemic anti-inflammatory effect in the vasculature and modulate the immune response. Here, we report the first case of a TAO patient at amputation risk treated with four sequential intravenous infusions of bone marrow-derived allogeneic MSCs from a healthy donor. Following administration, there was significant regression of foot skin ulcers and improvements in rest pain, Walking Impairment Questionnaire scores, and quality of life. Sixteen months after the infusion, the patient had not required any further amputations. This report highlights the potential of sequential allogeneic MSC infusions as an effective treatment for TAO, warranting further studies to compare this approach with the more conventionally used intramuscular MSC administration and other cell-based therapies. |
topic |
Allogeneic mesenchymal stromal cells Thromboangiitis obliterans Cell transplantation |
url |
http://link.springer.com/article/10.1186/s13287-018-0901-6 |
work_keys_str_mv |
AT jorgedmartinrufino sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT franciscoslozano sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT albamredondo sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT evamvillaron sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT raquelrueda sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT rafaelfernandezsamos sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease AT ferminsanchezguijo sequentialintravenousallogeneicmesenchymalstromalcellsasapotentialtreatmentforthromboangiitisobliteransbuergersdisease |
_version_ |
1725168531405799424 |